109 related articles for article (PubMed ID: 22993368)
1. Rapid relapse after resection of a sunitinib-resistant gastrointestinal stromal tumor harboring a secondary mutation in exon 13 of the c-KIT gene.
Kikuchi H; Miyazaki S; Setoguchi T; Hiramatsu Y; Ohta M; Kamiya K; Sakaguchi T; Konno H
Anticancer Res; 2012 Sep; 32(9):4105-9. PubMed ID: 22993368
[TBL] [Abstract][Full Text] [Related]
2. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H
Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
[TBL] [Abstract][Full Text] [Related]
3. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
4. Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.
Wada N; Kurokawa Y; Takahashi T; Hamakawa T; Hirota S; Naka T; Miyazaki Y; Makino T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Oncology; 2016; 90(2):112-7. PubMed ID: 26779618
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.
Guo T; Hajdu M; Agaram NP; Shinoda H; Veach D; Clarkson BD; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Clin Cancer Res; 2009 Nov; 15(22):6862-70. PubMed ID: 19861442
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
Yang W; Li K; Yu J; Shou C; Zhang Q; Hong Y; Sun J; Yu H; Gao Y; Shen Q; Zhao Z; Zheng S
Scand J Gastroenterol; 2018; 53(10-11):1328-1334. PubMed ID: 30346846
[TBL] [Abstract][Full Text] [Related]
7. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
8. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature.
Ito T; Yamamura M; Hirai T; Ishikawa T; Kanda T; Nakai T; Ohkouchi M; Hashikura Y; Isozaki K; Hirota S
Int J Clin Exp Pathol; 2014; 7(11):8024-31. PubMed ID: 25550846
[TBL] [Abstract][Full Text] [Related]
10. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
11. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.
Nishida T; Takahashi T; Nishitani A; Doi T; Shirao K; Komatsu Y; Nakajima K; Hirota S;
Int J Clin Oncol; 2009 Apr; 14(2):143-9. PubMed ID: 19390946
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.
Künstlinger H; Huss S; Merkelbach-Bruse S; Binot E; Kleine MA; Loeser H; Mittler J; Hartmann W; Hohenberger P; Reichardt P; Büttner R; Wardelmann E; Schildhaus HU
Am J Surg Pathol; 2013 Nov; 37(11):1648-59. PubMed ID: 24061512
[TBL] [Abstract][Full Text] [Related]
14. Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis.
Speight RA; Nicolle A; Needham SJ; Verrill MW; Bryon J; Panter S
J Clin Oncol; 2013 Jun; 31(16):e245-7. PubMed ID: 23610110
[No Abstract] [Full Text] [Related]
15. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
Zheng S; Jia J; Pan YL; Tao DY; Lu HS
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
[No Abstract] [Full Text] [Related]
16. [A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
Takeda Y; Nakahira S; Katsura Y; Ohmura Y; Kusama H; Kuroda Y; Goto T; Hashimoto T; Kimura K; Matsushita K; Sato Y; Morimoto Y; Ishida T; Nitta K; Kagawa Y; Okishiro M; Takeno A; Sakisaka H; Taniguchi H; Egawa C; Ohzono K; Nakatsuka S; Kato T; Tamura S
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1545-7. PubMed ID: 25731247
[TBL] [Abstract][Full Text] [Related]
17. KIT gene mutations in gastrointestinal stromal tumor.
Kang W; Zhu C; Yu J; Ye X; Ma Z
Front Biosci (Landmark Ed); 2015 Jun; 20(6):919-26. PubMed ID: 25961532
[TBL] [Abstract][Full Text] [Related]
18. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
19. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
Xu J; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353
[TBL] [Abstract][Full Text] [Related]
20. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]